跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04676672
NCT04676672进行中（未招募）不适用

NEOS - A Post-market Clinical Follow-up Study in Patients With Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated With E-vita OPEN NEO

JOTEC GmbH2 个研究点 分布在 2 个国家目标入组 163 人开始时间: 2020年12月3日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
JOTEC GmbH
入组人数
163
试验地点
2
主要终点
Mortality
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The NEOS post-market clinical follow-up study is undertaken to demonstrate the safety and clinical performance of E-vita OPEN NEO in the treatment of aneurysm or dissection in the ascending aorta, aortic arch and descending thoracic aorta.

详细描述

In this study, patients will be observed who receive an E-vita OPEN NEO implant for the treatment of thoracic aneurysm or acute or chronic thoracic dissection. E-vita OPEN NEO will be implanted according to the instructions for use and at the discretion of the treating physician.

Participating physicians will provide their observations collected during routine care for patients treated with E-vita OPEN NEO. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection.

The period of data collection will be approximately 60 months from the date of intervention for each patient. Source data verification will be performed on 100% of the patients; data from all the visits that was provided in the database will be reviewed and verified against existing source documents. Complete DICOM image files of the CT scans will be sent to the CoreLab for independent evaluation. All adverse events defined prior to study start will be adjudicated by the Clinical Event Committee (CEC).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Patient´s age is between 18 and 75 years.
  • •Patient is willing and able to comply with the standard follow-up visits planned after the implantation procedure.
  • •Patient is willing and able to give informed consent.
  • •Patient satisfies one of the following categories:
  • •Patient has acute / subacute aortic dissection and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires treatment, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta.
  • •Patient has chronic aortic dissection which requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta, and the patient satisfies one or more of the following criteria:
  • •Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥ 5.5 cm.
  • •Patient has aorta diameter < 5.5 cm and a growth rate of ≥ 0.5 cm / year. Patient has ascending aorta diameter ≥ 4.5 cm and requires an aortic valve repair or replacement.
  • •Patient has clinical signs of abdominal or peripheral malperfusion.
  • •Patient has a fusiform or saccular aortic aneurysm which requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta, and patient satisfies the following criteria:
  • •Patient has a suitable distal sealing area in the descending thoracic aorta proximal to the celiac trunk.
  • •And in case of fusiform aneurysm one of the following characteristics:
  • •Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥ 5.5 cm.
  • •Patient has aorta diameter < 5.5 cm and a growth rate of ≥ 0.5 cm / year. Patient has ascending aorta diameter ≥ 4.5 cm and requires an aortic valve repair or replacement.
  • •Patient is hemodynamically stable without pharmacological support at time of admission to the hospital (stable blood pressure and heart rate, no shock).

排除标准

  • •Patient is unfit for open surgical repair involving circulatory arrest.
  • •Patient has known sensitivities or allergies to nitinol, polyester, platinum-iridium, or polyethylene.
  • •Patient has systemic infection.
  • •Patient has endocarditis or active infection of the aorta.
  • •Patient has a free ruptured aorta.
  • •Patient has acute stroke or suspected acute stroke.
  • •Patient is on inotropes at time of arrival to the hospital.
  • •Patient needs mitral valve repair or replacement.
  • •Patient is enrolled or plans to be enrolled in another active study.
  • •Patient is pregnant or breastfeeding or planning to become pregnant during the course of the study.
  • •Patient has uncorrectable bleeding anomaly (i.e., thrombocytopenia).
  • •Patient has an eGFR < 45 ml/min/1.73m2 before the intervention
  • •Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated.
  • •Patient has co-morbidity (i.e. active malignancy (progressive, stable or partial remission)) causing expected survival to be less than 3 years.
  • •Patient has any other medical, social or psychological problems, that in the opinion of the investigator, preclude the patient from participating in this study.

结局指标

主要结局

Mortality

时间窗: 30-day

Rate of all-cause mortality

次要结局

  • Device technical success(24 hours)
  • Major Adverse Events(12 months)
  • Procedural success(At discharge, an avarage of 30 days)
  • Aortic rupture(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Additional intervention(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Disabling stroke(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Stenosis(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Migration(3-6, 12, 24, 36, 60 months)
  • Endoleak type II (aneurysm)(3-6, 12, 24, 36, 60 months)
  • Endoleak type Ib (dissection)(3-6, 12, 24, 36, 60 months)
  • Paraparesis(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Renal failure(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Endoleak type IV (aneurysm)(3-6, 12, 24, 36, 60 months)
  • Increasing aortic diameter(12, 24, 36, 60 months)
  • Stable aortic diameter(12, 24, 36, 60 months)
  • Stable or decreasing false lumen size(3-6, 12, 24, 36, 60 months)
  • Patent false lumen in stented region(3-6, 12, 24, 36, 60 months)
  • Mortality(30-day, 3-6, 12, 24, 36, 60 months)
  • Paraplegia(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Patency(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Endoleak type Ib (aneurysm)(3-6, 12, 24, 36, 60 months)
  • Decreasing aortic diameter(12, 24, 36, 60 months)
  • Treatment success(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Reintervention(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Aortic regurgitation(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Integrity(At discharge, an avarage of 30 days, 3-6, 12, 24, 36, 60 months)
  • Endoleak type III (aneurysm)(3-6, 12, 24, 36, 60 months)
  • Partially thrombosed false lumen between stent and celiac trunk(3-6, 12, 24, 36, 60 months)
  • Patent false lumen between stent and celiac trunk(3-6, 12, 24, 36, 60 months)
  • Obliterated false lumen between celiac trunk and aortic bifurcation(3-6, 12, 24, 36, 60 months)
  • Endoleak II (dissection)(3-6, 12, 24, 36, 60 months)
  • Endoleak type R (dissection)(3-6, 12, 24, 36, 60 months)
  • Increasing or stable true lumen size(3-6, 12, 24, 36, 60 months)
  • Obliterated false lumen between stent and celiac trunk(3-6, 12, 24, 36, 60 months)
  • Completely thrombosed false lumen between stent and celiac trunk(3-6, 12, 24, 36, 60 months)
  • Completely thrombosed false lumen between celiac trunk and aortic bifurcation(3-6, 12, 24, 36, 60 months)
  • Partially thrombosed false lumen between celiac trunk and aortic bifurcation(3-6, 12, 24, 36, 60 months)
  • Obliterated false lumen in stented region(3-6, 12, 24, 36, 60 months)
  • Completely thrombosed false lumen in stented region(3-6, 12, 24, 36, 60 months)
  • Partially thrombosed false lumen in stented region(3-6, 12, 24, 36, 60 months)
  • Patent false lumen between celiac trunk and aortic bifurcation(3-6, 12, 24, 36, 60 months)

研究者

发起方
JOTEC GmbH
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

进行中（未招募）
不适用
PMCF Study in Patients With Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated With E-vita OPEN NEOAortic DissectionAortic Aneurysm
NCT04986709JOTEC GmbH114
已完成
不适用
A post market clinical follow-up study with the Optimys Stem, with initial RSA analysisHip ArthroplastyHip replacement10023213
NL-OMON47653Stichting SCORE150
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac Death
NCT03319160Zoll Medical Corporation1,164
已完成
不适用
Post-market clinical follow-up study evaluating the efficacy and safety of the wearable cardioverter-defibrillator (WCD) medical device 'LifeVest' in real-life settings in France
ISRCTN91372291ZO550
已完成
不适用
A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense StrongJawline Contour Deficit
NCT06562075Bohus Biotech AB114
A PMCF Study in Patients With Acute or Chronic... | 临床试验